Another advantage to introducing urinary sCD163/creatinuria ratio determination as an LN biomarker is to overcome 24-h proteinuria and PCR limitations regarding tubular proteinuria (<25 kDa proteins) and the attribution of proteinuria to LN in a context of permanent renal damage, diabetes, hypertensive nephropathy, urinary tract infection, and other situations. The gene discussed is CD163; the disease is lobular neoplasia.